Marc Gruninger
At a glance: Marc Gruninger is Director at Veraxa Biotech AG - Post de-SPAC (VRXA). Their latest SEC Form 4, filed Oct 29, 2026, reported a purchase of $850. On file: 2 purchase lines ($10K) and 0 sale lines ($0).
Director at Veraxa Biotech AG - Post de-SPAC (VRXA)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys+$1K
Total bought / sold$10K / $0
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 29 NewSEC | VRXAVeraxa Biotech AG - Post de-SPAC | Buy | 867new position | $0.98 | $850 | +14.8% |
| Oct 29 NewSEC | VRXAVeraxa Biotech AG - Post de-SPAC | Buy | 9,13310,000 held (+1053%) | $1.00 | $9K | +12.5% |
- Buy
Director Marc Gruninger bought $850 of VRXA at $0.98 — first open-market purchase in our records; opens a new position.
- Buy
Director Marc Gruninger bought $9K of VRXA at $1.00 — largest purchase by this insider in our records; raises the stake by 1053%.